UOC
UBX

UBS O'Connor’s Unity Biotechnology UBX Stock Holding History

UBS O'Connor’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-79,354
Closed -$117K – 575
2024
Q3 		$117K Buy
79,354
+7,371
+10% +$10.8K ﹤0.01% 406
2024
Q2 		$97.2K Buy
71,983
+1,586
+2% +$2.41K ﹤0.01% 433
2024
Q1 		$115K Sell
70,397
-22,303
-24% -$38.7K ﹤0.01% 419
2023
Q4 		$179K Sell
92,700
-86,380
-48% -$161K 0.01% 399
2023
Q3 		$430K Hold
179,080
– – 0.01% 413
2023
Q2 		$457K Sell
179,080
-33,960
-16% -$89.7K 0.01% 449
2023
Q1 		$347K Buy
+213,040
New +$854K 0.01% 492
2022
Q4 		– Sell
-60,650
Closed -$240K – 314
2022
Q3 		$240K Buy
+60,650
New +$383K ﹤0.01% 839

Other funds holding UBX

AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
FFVM
Founders Fund V Management San Francisco, California $2.16M AUM 77.37% 1-Year Est. Return
CM
Cercano Management Bellevue, Washington $2.32B AUM 30.12% 1-Year Est. Return

UBS O'Connor's UBX Position: Q4 2024 in Review

UBS O'Connor sold out of Unity Biotechnology (UBX) in Q4 2024, closing a stake of 79,354 shares — an estimated $117K sold.

UBS O'Connor first reported a position in UBX in Q3 2022 and held it in 8 quarters. The position peaked at $457K in Q2 2023. 37 funds tracked by Wall St. Rank hold UBX as of Q4 2024.

  • UBS O'Connor reported no remaining Unity Biotechnology position as of Q4 2024 after selling out during the quarter.
  • UBS O'Connor sold 79,354 Unity Biotechnology shares in Q4 2024, an estimated $117K.
  • UBS O'Connor first reported a position in Unity Biotechnology in Q3 2022 and held it in 8 quarters.
  • UBS O'Connor's Unity Biotechnology position peaked at $457K in Q2 2023.
  • 37 funds tracked by Wall St. Rank held Unity Biotechnology as of Q4 2024.

Based on UBS O'Connor's 13F filing for Q4 2024, filed 14 Feb 2025.